Research programme: purinoceptor P2X3 antagonists - NEOMED

Drug Profile

Research programme: purinoceptor P2X3 antagonists - NEOMED

Alternative Names: NEO-5024; NEO-5937; P2X3 receptor antagonists - NEOMED

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NEOMED
  • Class Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Interstitial cystitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Interstitial-cystitis in Canada (PO)
  • 21 Oct 2013 NEO 5937 is available for licensing as of 21 Oct 2013.
  • 23 Nov 2012 Preclinical trials in Interstitial cystitis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top